» Articles » PMID: 32582550

Prostate Cancer Theranostics - An Overview

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Jun 26
PMID 32582550
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Metastatic prostate cancer is incurable, and novel methods to detect the disease earlier and to direct definitive treatment are needed. Molecularly specific tools to localize diagnostic and cytotoxic radionuclide payloads to cancer cells and the surrounding microenvironment are recognized as a critical component of new approaches to combat this disease. The implementation of theranostic approaches to characterize and personalize patient management is beginning to be realized for prostate cancer patients. This review article summarized clinically translated approaches to detect, characterize, and treat disease in this rapidly expanding field.

Citing Articles

Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.

Ismuha R, Ritawidya R, Daruwati I, Muchtaridi M Molecules. 2025; 29(24.

PMID: 39770150 PMC: 11679579. DOI: 10.3390/molecules29246062.


Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer.

Andrew J, Ezra-Manicum A, Witika B EJNMMI Radiopharm Chem. 2024; 9(1):62.

PMID: 39180599 PMC: 11344754. DOI: 10.1186/s41181-024-00295-7.


Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer.

Ritawidya R, Wongso H, Effendi N, Pujiyanto A, Lestari W, Setiawan H Adv Pharm Bull. 2023; 13(4):701-711.

PMID: 38022814 PMC: 10676551. DOI: 10.34172/apb.2023.079.


Safety assessment, radioiodination and preclinical evaluation of antinuclear antibody as novel medication for prostate cancer in mouse xenograft model.

Nguyen T, Hoang L, Nguyen T, Nguyen T, Nguyen Q, Nguyen T Sci Rep. 2023; 13(1):18753.

PMID: 37907691 PMC: 10618443. DOI: 10.1038/s41598-023-45984-6.


Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer.

Ng C, Bonilla H, Bryce A, Singh P, Herrmann J Curr Cardiol Rep. 2023; 25(8):889-899.

PMID: 37490155 PMC: 10894683. DOI: 10.1007/s11886-023-01909-3.


References
1.
Pandit-Taskar N, ODonoghue J, Beylergil V, Lyashchenko S, Ruan S, Solomon S . ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 41(11):2093-105. PMC: 4404641. DOI: 10.1007/s00259-014-2830-7. View

2.
Carver B . Strategies for targeting the androgen receptor axis in prostate cancer. Drug Discov Today. 2014; 19(9):1493-7. DOI: 10.1016/j.drudis.2014.07.008. View

3.
Hinkle G, Burgers J, Neal C, Texter J, Kahn D, Williams R . Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 1998; 83(4):739-47. View

4.
Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams Jr C, Thiele N . A Single Dose of Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model. J Nucl Med. 2018; 60(5):649-655. DOI: 10.2967/jnumed.118.219592. View

5.
Pedersen E, Shiozawa Y, Pienta K, Taichman R . The prostate cancer bone marrow niche: more than just 'fertile soil'. Asian J Androl. 2012; 14(3):423-7. PMC: 3602965. DOI: 10.1038/aja.2011.164. View